Product Information
ABILIFY MAINTENA ER 300 MG VL is a brand product labeled by Otsuka America Pharmaceutical Inc., priced at $2142.3765 per EA under NDC 59148023212. Its NADAC has been published 59 times since May 14, 2025.
The High Outlier badge above means this manufacturer's average price in the aripiprazole market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Manufacturer
Otsuka America Pharmaceutical Inc.NDC
59148023212
Classification
Brand
Dosage Form
KIT
Last Updated
6/17/2026
Approval Type
New Drug (NDA)
FDA Application
NDA202971On Market Since
2/28/2025
Price Statistics
The NADAC for ABILIFY MAINTENA ER 300 MG VL has been published 59 times since May 14, 2025, and over the history we have for it it has risen 3.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2142.3765 per EA |
|---|---|
| All-time high | $2144.5442 (Jun 10, 2026) |
| All-time low | $2077.0999 (Dec 17, 2025) |
| 52-week high | $2144.5442 |
| 52-week low | $2077.0999 |
| Median price | $2084.4539 |
| Average price | $2104.9322 |
| Largest weekly change | +3.0% (Jan 14, 2026) |
| Weeks tracked | 59 |
| Tracking since | May 14, 2025 |
Generic Alternatives
The matcher finds 1 NADAC-published product sharing this drug's active ingredient, strength, and dosage form across 1 manufacturer (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of ABILIFY MAINTENA ER 300 MG VL?
The current National Average Drug Acquisition Cost (NADAC) for ABILIFY MAINTENA ER 300 MG VL, manufactured by Otsuka America Pharmaceutical Inc., is $2142.3765 per EA (NDC 59148023212), effective Jun 24, 2026.
How has the price of ABILIFY MAINTENA ER 300 MG VL changed over time?
Over the history we have for it, the NADAC for ABILIFY MAINTENA ER 300 MG VL has risen 3.0%. It has been tracked across 59 weekly CMS publications since May 14, 2025.
What are the highest and lowest recorded NADAC prices for ABILIFY MAINTENA ER 300 MG VL?
Since May 14, 2025, the NADAC for ABILIFY MAINTENA ER 300 MG VL has ranged from a low of $2077.0999 (Dec 17, 2025) to a high of $2144.5442 (Jun 10, 2026), with a median of $2084.4539 per EA.
Are there cheaper alternatives to ABILIFY MAINTENA ER 300 MG VL?
Yes. 1 NADAC-published product shares the same active ingredient, strength, and dosage form. The lowest-priced option, ABILIFY MAINTENA ER 300 MG SYR, is $2137.3167 per EA — about 0% below ABILIFY MAINTENA ER 300 MG VL.
Who manufactures ABILIFY MAINTENA ER 300 MG VL?
ABILIFY MAINTENA ER 300 MG VL (NDC 59148023212) is labeled by Otsuka America Pharmaceutical Inc., and CMS classifies it as a brand product.
Related Drugs
Same classification